Respiratory Research Analysis
March respiratory research converged on transmission science, post-viral oncogenic risk, antifibrotic therapy, and bedside biomarker-guided care. Human challenge data directly quantified person-to-person heterogeneity in expelling infectious influenza, refining targeted infection control. Severe viral pneumonia was mechanistically linked to accelerated lung cancer growth, nominating vaccination and neutrophil/PD-(L)1 blockade as mitigation strategies. A large randomized follow-up supported neran
Summary
March respiratory research converged on transmission science, post-viral oncogenic risk, antifibrotic therapy, and bedside biomarker-guided care. Human challenge data directly quantified person-to-person heterogeneity in expelling infectious influenza, refining targeted infection control. Severe viral pneumonia was mechanistically linked to accelerated lung cancer growth, nominating vaccination and neutrophil/PD-(L)1 blockade as mitigation strategies. A large randomized follow-up supported nerandomilast as a disease-modifying option in progressive pulmonary fibrosis, and a pragmatic phase 3 ED trial showed rapid procalcitonin testing reduced 28-day mortality. Structural immunology also advanced drift-resilient influenza B antibody and immunogen design.
Selected Articles
1. Controlled human influenza infection reveals heterogeneous expulsion of infectious virus into air.
In a modular sampling tunnel, investigators directly captured, cultured, quantified, and sequenced infectious influenza from exhaled particles of experimentally infected humans. Emission magnitude varied by orders of magnitude across individuals, correlated with infectious loads in saliva/nasopharynx and symptoms, and preserved within-host viral diversity.
Impact: Provides rare, direct human evidence linking infectious aerosol emission to clinical and virologic markers, enabling refined transmission modeling and targeted infection control.
Clinical Implications: IPC should account for high emitters and symptom-linked peaks with targeted masking, ventilation, and testing priorities; surveillance can incorporate aerosol culture/sequencing to preserve diversity for genomic tracking.
Key Findings
- Infectious virus from exhaled particles was captured, cultured, quantified, and sequenced in humans.
- Emission varied over several orders of magnitude between individuals and correlated with symptoms and infectious loads.
- Expelled aerosols preserved within-host viral diversity similar to clinical samples.
2. Respiratory viral infections prime accelerated lung cancer growth.
Human observational data and murine models show severe viral pneumonia durably reprograms the lung into a neutrophil-rich, immunosuppressive niche that accelerates tumor growth; vaccination mitigated the effect, and combined neutrophil-recruitment plus PD-L1 blockade restored CD8+ T-cell function and reduced tumors.
Impact: Links acute severe respiratory infection to subsequent lung tumor progression and nominates actionable prevention and treatment strategies.
Clinical Implications: Support enhanced post-pneumonia surveillance, reinforce vaccination, and prioritize trials of neutrophil-targeting plus PD-(L)1 strategies for patients with recent severe viral pneumonia.
Key Findings
- Severe viral pneumonia creates a durable, neutrophil-rich immunosuppressive niche that accelerates tumor growth.
- Prior vaccination mitigates infection-enhanced tumor progression.
- Neutrophil recruitment blockade combined with PD-L1 inhibition restores CD8+ T-cell function and reduces tumors.
3. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Among 1,176 patients with progressive pulmonary fibrosis and mean 17 months observation, nerandomilast reduced the composite of first AE-ILD, respiratory hospitalization, or death (HR ~0.77–0.78 vs placebo) with favorable tolerability; benefits were larger without background nintedanib.
Impact: Provides large randomized, extended follow-up evidence for a disease-modifying antifibrotic that lowers clinically meaningful events in progressive pulmonary fibrosis.
Clinical Implications: Consider nerandomilast as a disease-modifying option, particularly in patients not receiving nintedanib, with monitoring for event reduction and long-term safety.
Key Findings
- Reduced composite of first AE-ILD, respiratory hospitalization, or death (HR 0.77–0.78).
- Greater benefit in patients not on background nintedanib (HR 0.65–0.69).
- Favorable safety and tolerability over prolonged follow-up.
4. Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial.
In a pragmatic multicentre phase 3 trial (>7,600 randomized), adding rapid procalcitonin to NEWS2-based ED care did not change 3-hour IV antibiotic initiation but significantly reduced 28-day mortality (13.6% vs 16.6%; adjusted risk difference −3.12 percentage points) without increasing adverse events.
Impact: Demonstrates that integrating a rapid biomarker into routine ED assessment improves survival in suspected sepsis, with immediate pathway and policy relevance.
Clinical Implications: EDs should evaluate integrating rapid procalcitonin into NEWS2-based pathways, ensuring workflow fit, clinician adherence, and stewardship monitoring to achieve mortality reduction without excess early antibiotic exposure.
Key Findings
- 3-hour IV antibiotic initiation was similar between groups (~48%).
- 28-day mortality was significantly lower with procalcitonin-guided care.
- No increase in adverse events; clinicians incorporated PCT in most guided decisions.
5. Human monoclonal antibodies isolated after seasonal vaccination broadly neutralize antigenically drifted influenza B viruses.
Two human bnAbs (CAV-CF22, CAV-CH76) isolated post-vaccination neutralize contemporary Victoria and Yamagata influenza B lineages and protect in vivo. Structures show HCDR3 insertion into the HA receptor-binding site to mimic sialic acid, conferring breadth and resilience to K136E drift.
Impact: Reveals a drift-resilient neutralization mechanism and candidate bnAbs that directly inform next-generation influenza B immunogen and therapeutic design.
Clinical Implications: Guides immunogen design toward conserved RBS features and supports development of bnAb therapeutics robust to K136E drift; surveillance of HA-136 variants should inform vaccine updates.
Key Findings
- Two human bnAbs broadly neutralized Victoria and Yamagata influenza B lineages and protected in vivo.
- Post-2019 IBV strains escaped several prior head-directed bnAbs due to K136E fixation.
- HCDR3 insertion into the RBS sterically mimics sialic acid, explaining breadth and drift resilience.